Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Comparative Phase III Study Including Patients With CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer.

NCT07103668 is registered in ClinicalTrials.gov with Suzhou Immunofoco Biotechnology Co., Ltd as lead sponsor.

NCT NCT07103668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07103668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Comparative Phase III Study Including Patients With CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer.
Lead sponsor
Suzhou Immunofoco Biotechnology Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
August 6, 2025
Completion date
May 31, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma